



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/36, 38/27, 38/30, C08B 37/08		A1	(11) International Publication Number: WO 95/18635 (43) International Publication Date: 13 July 1995 (13.07.95)
<p>(21) International Application Number: PCT/SE95/00011</p> <p>(22) International Filing Date: 10 January 1995 (10.01.95)</p> <p>(30) Priority Data: 9400036-1 10 January 1994 (10.01.94) SE</p> <p>(71) Applicant (<i>for all designated States except US</i>): PHARMACIA AB [SE/SE]; S-171 97 Stockholm (SE).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (<i>for US only</i>): JEDERSTRÖM, Gustav [SE/SE]; Rörstrandsgatan 22, S-113 40 Stockholm (SE).</p> <p>(74) Agents: TANNERFELDT, Agneta et al.; Pharmacia AB, S-171 97 Stockholm (SE).</p>		<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: **LOW MOLECULAR WEIGHT HYALURONIC ACID WITH PEPTIDE OR PROTEIN**

(57) Abstract

The invention relates to freeze-dried soft, flexible and continuous matrix of low-molecular weight hyaluronic acid or salt thereof, in which the molecular weight of the hyaluronic acid is preferably between 50 000 and 200 000 Da, containing at least one peptide or protein. It also relates to a pharmaceutical composition in the form of a layer which is characterised by this freeze-dried low-molecular weight hyaluronic acid containing at least one peptide or protein. The drug is preferably chosen from at least one of GH, IGF-I, IGF-II and/or EGF and could be mixed with an antibiotic agent. The process for the manufacture of this matrix and the use of the pharmaceutical composition for the manufacturing of a drug for wound healing is claimed. The invention discloses a method for accurately obtaining a predetermined dosage of a topically administerable drug which is characterised by freeze-drying a water solution of low-molecular weight hyaluronic acid and the peptide or protein to form a layer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

LOW MOLECULAR WEIGHT HYALURONIC ACID WITH PEPTIDE OR PROTEIN

5

The invention relates to a freeze-dried soft, flexible and continuous matrix of low-molecular weight hyaluronic acid or salt thereof containing at least one peptide or protein, useful as pharmaceutical composition.

10 Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan consisting of a linear polymer of repeating units of glucuronic acid and N-acetyl-glucosamine. The molecular weight can vary over a wide range depending on the source. HA is present in several tissues of animals, and in some organs, such as rooster combs, in concentrations high enough for commercial scale extraction. Such tissue contains HA of a wide range of molecular weights and during a complex series of 15 extraction, purification and sterilisation steps, high molecular weight chains are more or less degraded resulting in a final product having a considerably narrower molecular weight range. The critical parameters determining the characteristics of the final product in this respect are the molecular weight distribution of HA in 20 the raw material, the degree of degradation of HA chains during the purification and sterilisation process and the effectiveness of removing 25 low molecular weight HA.

30 A commercial available hyaluronic acid product is HEALON® (Kabi Pharmacia AB, Uppsala, Sweden) which has a average molecular weight of about 4 000 000 daltons. This product is produced as outlined in USA 4 141 973 and is an ultrapure product. There are many literature 35 references relating to the use of viscoelastic products of HA in ophthalmological application and the preparation of such products, including the preparation of chemically modified HA.

HA is known in slow release formulations and in WO 9005522 HA is mentioned as a slow release carrier together with a binding protein for e.g. GH or IGF.

5 In US 4772419 a shaped article based upon cross-linked, possible derivatized HA or salt thereof, which is a substantially unswollen water-swellable state has a dry matter content of at least 65 percent by weight and a tensile strength greater than 100 N/cm² is disclosed. HA is of high molecular weight, i.e. about 3 000 000 Da. The article
10 could be produced by freeze-drying. Thin sheets of paper-like structure or cellophane-like structures were obtained. The article could be used for preventing the adhesion and accretion of tissues.

15 Low molecular weight hyaluronic acid (LMWHA) could be produced by acid or enzymatic hydrolysis and thereafter fractionation. These processes are known in the art.

LMWHA is known as carrier for pharmaceutical active agents and also for pharmaceutical activity itself.

20 In EP 138 572 a product comprising HA with Mw of 50 000 - 100 000 is stated as useful for wound healing and HA with a Mw of 500 000 - 730 000 is useful for intraocular and intra-articular injections. Fragments of HA as carrier for drugs, e.g. EGF, in eyedrops is also disclosed.

25 In EP 197 718 HA with different Mw between 30 000-730 000 is useful in the ophthalmic and dermatologic field. LMWHA with EGF is mentioned as example.
HA with Mw of 500-800 000 together with water for cosmetic and skin disorder is known from GB 2 228 736.

30 In US 5 079 236 HA with Mw 50 000- 200 000 for treatment of osteoarthritis and joint function is disclosed and in JP 1 290 631 HA with Mw 50 000-3 000 000 for treatment of arthrosis, diabetic retinopathy is claimed.
WO 9316732 and WO 9316733 disclose HA or fragments thereof (e.g. < 750 000) and a drug e.g. anti-inflammatory NSAID, diclofenac, naproxen, anti-cancer, especially useful topically for skin.

In GB 2 235 204 is disclosed that a readily water-soluble film or sheet for cosmetic use is formed when hyaluronic acid is freeze-dried in vacuo. The hyaluronic acid used has a molecular weight of 1 200 000, giving a viscous solution in water. The layer containing 5 magnesium-L-ascorbil phosphate is used as a cosmetic sheet for a face mask. Skin moisture, skin tension and whitening effect was shown for this composition.

EP 522 491 discloses a freeze-dried composition comprising 10 hyaluronic acid and a polypeptide, which is administered by injection after reconstitution of the composition.

Our claimed composition comprises low molecular weight 15 hyaluronic acid and peptide or protein, which gives unexpected advantageous effect when used for administration of a drug.

For the production of a matrix, which is soft, flexible and continuous and preferably in the form of a layer, special binding forces and interactions within the molecule are needed. Hyaluronic acid with a 20 high molecular weight has a special structure of the molecule, which cannot be compared the molecular structure of the low molecular weight hyaluronic acid. A person skilled in the art could not foresee how the low molecular weight hyaluronic acid could react when freeze-dried.

25 When administrating a drug topically, a problem is to know how much drug is released during a certain time, so that the patient always receives the right dosage per time unit.

When giving the drug dropwise on an ulcer, the total amount is well 30 defined but there are difficulties in the administration of the drug in a defined amount over the whole surface and this method requires normally clinical care.

When giving the drug in a paste-base, the exact amount of the drug is difficult to calculate and apply. Difficulties for sublingual or buccal 35 composition can e.g. be stability problem due to a hydrophilic character of the base or calculation of the release time.

We have now found that when freeze-drying an aqueous solution of a peptide or protein and LMWHA which is not cross-linked, a layer in the form of a cake is formed with a structure like a wovens or a filter

5 paper. The "paper" is porous, massive and homogenous.

This "paper" can be cut in a desired form, can be torn and is easily handled. For this "paper" the exact amount of the drug per area is known. This means that the dosage can be accurate when the area of the "paper" is known.

10 We have also found that when applying this "paper" topically, sublingually or buccally, the whole amount of the drug is quickly released.

The drug is stable and keeps the activity within this formulation during storage.

15 The claimed formulation is biocompatible when applied on humans and is a perfect mean for treatment of ulcers of different kind.

The "paper" or "cake" can be applied directly to the ulcer or in the mouth. The drug will be thereby be quickly released by the pus or the saliva.

20 We have also found that the drug can be present in a high concentration when freeze-dried together with low molecular weight HA.

25 The present invention relates thus to a freeze-dried soft, flexible and continuous matrix of low-molecular weight hyaluronic acid or salt thereof containing at least one peptide or protein.

The molecular weight of the low-molecular weight hyaluronic acid is preferably between 50 000 and 200 000 Da.

30 The invention also relates to pharmaceutical compositions in the form of a layer characterised by a freeze-dried low-molecular weight hyaluronic acid containing at least one peptide or protein. The drug could be e.g. GH, IGF-I, IGF-II or EGF or mixtures thereof.

35 By GH is meant growth hormone or functional analogues thereof, by IGF is meant insulin-like growth factor or functional analogues thereof, both IGF-I and IGF-II and by EGF is meant epidermal growth factor or functional analogues thereof.

An antibiotic agent can be mixed with a growth hormone or growth factor when applied to a wound.

By functional analog is meant a substance having the same biological

5 activity as the peptide or protein and having at least 65 % homology with the peptide or protein.

The invention relates also to a process for the manufacture of the matrix or the pharmaceutical composition, which is characterised by

10 freeze-drying a water solution of low-molecular weight hyaluronic acid and the peptide or protein in a layer. This freeze-drying and further production of the pharmaceutical article must be sterile.

The invention also relates to the use of freeze-dried low molecular

15 weight hyaluronic acid in the form of a layer as carrier for peptide or protein

This use is preferably for accurate dosing of the drug.

The invention also relates to the use of the claimed pharmaceutical

20 composition for the manufacture of a medicament for wound healing and to a method for accurately obtaining a pre-determined dosage of a topically administerable peptide or protein which is characterised by freeze-drying a water solution of low-molecular weight hyaluronic acid and the peptide or protein to form a layer.

25 By low molecular weight is meant less than 1 000 000 D and preferably between 50 000 and 200 000 D.

The layer can be between 1-40 mm and is preferably 2-12 mm.

GH can be in a concentration of 1-200 IU/ml and is preferably 5-120 IU/ml.

30 pH can be between 6.0 and 8.2 in the water solution prior to freeze-drying.

Growth hormone is here used as an example for the usefulness of the invention, but is not limiting the scope of protection by the claims.

STABILITY OF PROTEINS

The stability of proteins depends on the chemical and physical properties of the protein.

5 Different degradation pathways are known such as deamidation, oxidation, cleavage and aggregation.

Deamidation and oxidation are common chemical reactions comprising changes of the primary structure of the protein. Deamidation occurs 10 especially in aqueous solutions but low temperature and low pH of the solutions suppress the deamidation reaction.

Different forms of aggregation result from the physical instability of 15 the protein. Aggregates can be soluble or insoluble and binding of both the forms can be covalent or non covalent.

The aggregates can give opalescent solutions but there can also be non-visible aggregation which only can be shown chemically.

The prevention of covalent aggregation in protein formulations is of 20 importance since such processes are irreversible and could result in the production of inactive species which in addition also may be immunogenic.

Changes in the primary structure may also give rise to conformational changes which can be the cause of self association of the protein, aggregation.

25 The non covalent aggregation occurring under certain conditions can lead to precipitation and loss of activity.

However, by monitoring these degradation reactions, it is possible to 30 prove indirectly that the drug (in the examples GH) retains full biological activity. (Bristow A F et al. Pharmeuropa, Human Growth Hormone, Vol.3, 1-49, March 1991)

METHODS

Isoelectric focusing (IEF) with densitometric evaluation

5 IEF is a method according to which the extent of deamidation can be evaluated.

The separation of hGH components is carried out in a pH gradient, which is established between two electrodes and stabilised by carrier ampholytes. The proteins migrate until they align themselves at their

10 isoelectric point in the gradient, at which a protein possesses no net overall charge and will therefore concentrate as migration ceases. Thus the separation is obtained according to charge. The relative distribution of charged hGH forms are quantified by densitometric scanning of Coomassie Blue stained polypeptides.

15 The higher percentage of the monomer, the less deamidation.

Polypeptides size distribution (SDS-PAGE)

Proteins in preparations of somatropin, hGH, were denatured by sodium dodecyl sulphate (SDS) to yield negatively charged molecular

20 complexes of SDS-protein. Separation was then obtained according to molecular size by electrophoresis in polyacrylamide gels (PAGE) in the presence of SDS. The relative polypeptide size distribution of hGH was quantified by desitometric scanning of the silver stained polypeptide bands.

25

Visual inspection

The appearance of the solutions were eye-inspected according to Ph. Eur. 2nd Ed. The scale is I to IV, and I is the most clear.

30

EXAMPLES

Example 1.

Hyaluronic acid with a molecular weight of about 150 000 dalton has been produced from Na- hyaluronate. 2.51 g of Na- hyaluronate (Pharmacia AB, Sweden) was solved in 500 ml of water in argon atmosphere.

16 ml HCl was added and the mixture was thereafter stirred during 2 hours at 22-23 °C. pH was <1. The solution was neutralised to pH 7.0 with 0.5 M NaOH. Thereafter 0.37 M HCl was added and the solution was stirred during 5 hours at 45 °C. in argon atmosphere. pH 7.0 was

5 then achieved with 0.5 M NaOH.

The solution was dialysed by using a dialyse tube with distilled water. The used tube was 130885/10 30M with a cut off 12-14 x10³ D.

10 The molecular weight of hyaluronic acid was analysed in the solution and the hyaluronic acid was freeze-dried.

15 The freeze-drying was performed during 30 hours in a rotation freeze-drier at -5°C to -50°C.

Example 2

15 Hyaluronic acid with a molecular weight (LMWHA) of 150 000 in water is mixed with growth hormone (GH, Genotropin® from Pharmacia AB, Sweden) so that each ml comprises 6.5 mg LMWHA and 110 IU GH. 10 ml of the solution is placed in a Petri dish with diameter of 70 mm with cover. The solutions are freeze-dried according to the

20 following scheme:

Freezing: 0--5°C during 3 hours
-45 °C during 26 hours

25 1st drying: -30°C during 28 hours at 0.1 mBar

2nd drying +25°C during 5-6 hours at 0.1 mBar

After storage at 5-8°C during one month the cake is dissolved in 2 ml destillated water and analyzed. The following result were obtained:

30 (Table 1)

Table 1

Tests:

5	1. dissolving time (min)	5
	2. clarity	II
	3. SDS-PAGE	
	aggregates (%)	0.6
	GH (%)	98.8
	Fragment (%)	0.7
10	4. IEF	
	Main component (%)	99
	deamidation (%)	0

15 Example 3

Hyaluronic acid with a molecular weight (LMWHA) of 150 000 is mixed with growth hormone (GH) (Genotropin® from Kabi Pharmacia AB, Sweden) in the following way: 65 mg hyaluronic acid was mixed with 2.65 ml of Genotropin®, 76 IU/ml. and diluted to 10 ml with distilled water, so that each ml comprises 6.5 mg LMWHA and 20.1 IU GH.

20 10 ml of the solution is dispensed in Petri dish with the diameter of 70 mm diameter with cover. The solutions are freeze-dried as described in Example 2.

25 The freeze-dried cake is as a filter paper which can be bent and be cut. The diameter is 6.0 cm and the thickness is 0.5 cm.

1 cm² of the cake is formulated to contain 7.1 IU Genotropin® and 2.3 mg hyaluronic acid, 150 000 dalton.

1 cm² of the cake is cut out and analysed. See Table 2

Table 2

		Months		
	0	1	1	
5	Tests:	5°C	30°C	
	1. Dissolving time (min)	1	2	3
	2. SDS-PAGE			
	aggregates (%)	0.5	2.9	4.5
	GH (%)	99	96.2	94.5
10	3. IEF			
	Fragment (%)	0.5	0.8	1.0
	Main component (%)	99	97	94
	deamidation (%)	1	1	0

15

The results for the claimed formulation confirms that a drug in a freeze-dried matrix of low-molecular weight hyaluronic acid can be stored in room temperature for at least one month in 30°C.

20 This result was surprising, as proteins and especially GH normally are unstable and not possible to store in room temperature for such a long time.

25 By a biological assay, nephelometry, the amount of GH per area unit was determined. It was found that the growth hormone was uniformly (homologeously) dispersed in the cake.

These results demonstrates indirectly that growth hormone retains full biological activity, since little or no degradation was observed after storage of growth hormone formulated with freeze-dried low molecular hyaluronic acid.

CLAIMS

5

1. Freeze-dried soft, flexible and continuous matrix of low-molecular weight hyaluronic acid or salt thereof containing at least one peptide or protein.

10 2. Freeze-dried matrix according to claim 1 in which the molecular weight of the hyaluronic acid is between 50 000 and 200 000 Da.

15 3. Pharmaceutical composition in the form of a layer characterised by a freeze-dried low-molecular weight hyaluronic acid containing at least one peptide or protein.

4. Pharmaceutical composition according to claim 4 in which the drug is chosen from at least one of GH, IGF-I, IGF-II and/or EGF.

20 5. Pharmaceutical composition according to claim 4 in which the drug is a mixture of GH, IGF-I, IGF-II and/or EGF and an antibiotic agent.

25 6. Process for the manufacture of the matrix according to claim 1 or a pharmaceutical composition according to claim 3 characterised by freeze-drying a water solution of low-molecular weight hyaluronic acid and the peptide or protein in a layer.

7. Use of a pharmaceutical composition according to claim 3 for the manufacturing of a medicament for wound healing.

30 8. Use of freeze-dried low molecular weight hyaluronic acid in the form of a layer as carrier for a peptide or protein.

35 9. Use according to claim 7 for accurate dosing of the peptide or protein.

10. Method for accurately obtaining a pre-determined dosage of a
topically administerable peptide or protein, characterised by freeze-
drying a water solution of low-molecular weight hyaluronic acid and
5 the peptide or protein to form a layer.

1
INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00011

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 47/36, A61K 38/27, A61K 38/30, C08B 37/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K, C08B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, WPIL, CLAIMS, EMBASE, MEDLINE, CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO, A1, 9402517 (ANIKA RESEARCH, INC.), 3 February 1994 (03.02.94) --	1-10
X	EP, A1, 0522491 (TAKEDA CHEMICAL INDUSTRIES, LTD), 13 January 1993 (13.01.93), page 4, line 31 - line 33	1-2
Y	--	1-10
Y	GB, A, 2235204 (CHISSO CORPORATION), 27 February 1991 (27.02.91) --	1-10

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 April 1995	05-05-1995
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86	Authorized officer Anneli Jönsson Telephone No. + 46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

2

International application No.

PCT/SE 95/00011

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP, A2, 0138572 (FIDIA SPA), 24 April 1985 (24.04.85) -- -----	1-10

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

25/02/95

PCT/SE 95/00011

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A1- 9402517	03/02/94	NONE		
EP-A1- 0522491	13/01/93	EP-A-	0503583	16/09/92
		JP-A-	5065231	19/03/93
		JP-A-	5186362	27/07/93
GB-A- 2235204	27/02/91	DE-A-	4024180	07/02/91
		FR-A-	2650180	01/02/91
		JP-A-	3063209	19/03/91
		JP-A-	3112914	14/05/91
EP-A2- 0138572	24/04/85	SE-T3-	0138572	
		AU-A-	3414884	18/04/85
		BE-A-	900810	11/04/85
		CA-A-	1205031	27/05/86
		CH-A,B-	666897	31/08/88
		FR-A-	2553099	12/04/85
		LU-A-	85582	04/06/85
		US-A-	5166331	24/11/92
		JP-B-	6008323	02/02/94
		JP-A-	61028503	08/02/86

